Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma

HIGHLIGHTS

  • who: Da Liu from the Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China have published the research: Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma, in the Journal: (JOURNAL)
  • what: In this study, compared with normal tissues and CM patients with low CRRS, CLEC2B was significantly downregulated in CM patients and CM patients with high CRRS.
  • how: Showed that the prognostic capability and stability of the combined model was greatly improved compared to each single variable alone. The authors used the Kaplan-Meier method . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?